Establishment of multicenter COVID-19 therapeutics preclinical test system in Republic of Korea

[1]  J. Yun,et al.  Comparison of the pathogenesis of SARS-CoV-2 infection in K18-hACE2 mouse and Syrian golden hamster models , 2022, Disease models & mechanisms.

[2]  Yuzhang Wu,et al.  SARS-CoV-2 Induces Lymphocytopenia by Promoting Inflammation and Decimates Secondary Lymphoid Organs , 2021, Frontiers in Immunology.

[3]  N. Krogan,et al.  Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A , 2021, Science.

[4]  P. Tarighi,et al.  A review of potential suggested drugs for coronavirus disease (COVID-19) treatment , 2021, European Journal of Pharmacology.

[5]  M. T. Medina,et al.  Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results , 2020, The New England Journal of Medicine.

[6]  R. Srinivasan,et al.  Selection of animal models for COVID-19 research , 2020, VirusDisease.

[7]  A. Pollard,et al.  What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2 , 2020, The Lancet Infectious Diseases.

[8]  Chao Zhang,et al.  Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) , 2020, Human vaccines & immunotherapeutics.

[9]  O. Tsang,et al.  Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. , 2020, JAMA.

[10]  Shamus P. Keeler,et al.  SARS-CoV-2 infection of hACE2 transgenic mice causes severe lung inflammation and impaired function , 2020, Nature Immunology.

[11]  H. Poor,et al.  Pulmonary Vascular Dilatation Detected by Automated Transcranial Doppler in COVID-19 Pneumonia , 2020, American journal of respiratory and critical care medicine.

[12]  J. Yun,et al.  Advances in selecting appropriate non-rodent species for regulatory toxicology research: Policy, ethical, and experimental considerations. , 2020, Regulatory toxicology and pharmacology : RTP.

[13]  C. Hallam,et al.  Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice , 2020, Nature Communications.

[14]  G. Tiram,et al.  Immune-mediated approaches against COVID-19 , 2020, Nature Nanotechnology.

[15]  P. Moschella,et al.  Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review , 2020, Viruses.

[16]  C. Pelliccia,et al.  The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 , 2020, European Journal of Clinical Pharmacology.

[17]  Tokiko Watanabe,et al.  Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development , 2020, Proceedings of the National Academy of Sciences.

[18]  J. Abraham.  Passive antibody therapy in COVID-19 , 2020, Nature Reviews Immunology.

[19]  C. Page,et al.  Animal models of mechanisms of SARS‐CoV‐2 infection and COVID‐19 pathology , 2020, British journal of pharmacology.

[20]  George Nicolae Daniel Ion,et al.  Comprehensive analysis of drugs to treat SARS-CoV-2 infection: Mechanistic insights into current COVID-19 therapies (Review) , 2020, International journal of molecular medicine.

[21]  J. Thachil,et al.  Coagulation abnormalities and thrombosis in patients with COVID-19 , 2020, The Lancet Haematology.

[22]  L. Amorosa,et al.  An Update on Current Therapeutic Drugs Treating COVID-19 , 2020, Current Pharmacology Reports.

[23]  G. Kai,et al.  COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons , 2020, Cytokine & Growth Factor Reviews.

[24]  Yi Wang,et al.  Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial , 2020, The Lancet.

[25]  T. Jodlowski,et al.  Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. , 2020, JAMA.

[26]  K. To,et al.  Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  D. Wang,et al.  The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status , 2020, Military Medical Research.

[28]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[29]  Peter Daszak,et al.  Escaping Pandora's Box - Another Novel Coronavirus. , 2020, The New England journal of medicine.

[30]  Wenling Wang,et al.  The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice , 2020, Nature.

[31]  Suryanarayana Yaddanapudi,et al.  Changing Trends in Computational Drug Repositioning , 2018, Pharmaceuticals.

[32]  J. Stauffer,et al.  Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis , 2017, European Respiratory Review.

[33]  Cheryl L. Scudamore,et al.  Practical approaches to reviewing and recording pathology data , 2013 .

[34]  Robert Klopfleisch,et al.  Multiparametric and semiquantitative scoring systems for the evaluation of mouse model histopathology - a systematic review , 2013, BMC Veterinary Research.

[35]  David K. Meyerholz,et al.  Lethal Infection of K18-hACE2 Mice Infected with Severe Acute Respiratory Syndrome Coronavirus , 2006, Journal of Virology.

[36]  M. Nord,et al.  Regulation of the Clara Cell Secretory Protein/Uteroglobin Promoter in Lung , 2000, Annals of the New York Academy of Sciences.

[37]  A. Bernard,et al.  Clara cell secretory protein (CC16): characteristics and perspectives as lung peripheral biomarker , 2000, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[38]  W. Lim,et al.  Dexamethasone in Hospitalized Patients with Covid-19 , 2021 .

[39]  H. Yen,et al.  Peer Review File Manuscript Title: Pathogenesis and transmission of SARS-CoV-2 in golden Syrian hamsters , 2020 .

[40]  David Smith.  The Selection of Non-rodent species for Pharmaceutical Toxicology , 2010 .

[41]  James P. Evans.  The Origin , 2009, Genetics in Medicine.

[42]  T. Weaver,et al.  Function of surfactant proteins B and C. , 2001, Annual review of physiology.

[43]  E. Glaser.  The randomized clinical trial. , 1972, The New England journal of medicine.